Fluidx Medical Technology, Inc.
- Industry
- Medical Devices & Equipment
- Founded Year
- 2015
- Headquarters
- Salt Lake City, UT, USA
- Employee Count
- 7
Key People
- Libble Ginster - President & CEO
- Karen Ginster - Co-Chief Executive Officer & Board Member
- James McGuckin MD - Co-Founder & Board Member
- Shawn Fojtik - Co-Founder & Board Member
- Russell Stewart Ph.D - Co-Founder
- Danny Smith - Vice President of Research and Development
- Russell Bjorklund - Vice President, Marketing and Strategy
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced MedTech entrepreneurs and industry leaders.
The presence of multiple successful MedTech entrepreneurs in the leadership team suggests a strong foundation for strategic decision-making and innovation.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's embolic devices address critical needs in embolization procedures.
By focusing on improving embolization procedures, the company targets a vital area in interventional medicine, indicating a substantial market demand.
- Competition
-
Aspect: Somewhat crowded
Summary: The embolic device market has several established players.
While the market is somewhat crowded, the company's innovative approach may provide a competitive edge if effectively communicated and demonstrated.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing embolic devices involves moderate technical challenges.
The development of embolic devices requires addressing specific technical challenges, but these are manageable with the right expertise and resources.
- Patent
-
Aspect: Strong
Summary: The company holds several patents related to its embolic devices.
Holding multiple patents provides the company with intellectual property protection, which is crucial for maintaining a competitive advantage in the market.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding, including a Series A round.
Securing a Series A funding round indicates investor confidence and provides the necessary capital for advancing clinical trials and preparing for market entry.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The company is preparing for pivotal clinical trials.
Engaging in pivotal trials is a significant step toward regulatory approval, but it also presents challenges that must be carefully managed to ensure success.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 5.7
- Segment CAGR
- 9.4%
- Market Segment
- Interventional Oncology
- Market Sub Segment
- Embolic Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Fluidx Medical Technology is well-positioned in the embolic device market, leveraging a strong team and innovative products to address significant clinical needs, though it faces challenges in a competitive and regulated environment.